智通财经APP获悉，云顶新耀(01952)涨超5%，截至发稿，涨4.07%，报48.56港元，成交额1.58亿港元。
消息面上，据云顶新耀官微消息，在2025年第58届美国肾脏病协会肾脏周(ASN Kidney Week 2025)上，耐赋康®(布地奈德肠溶胶囊，NEFECON®)展示了多项关于IgA肾病患者的最新研究结果。随着耐赋康®在中国人群中证据的不断积累，这些研究结果进一步证实了在“对因治疗、尽早治疗、长期治疗”IgA肾病新管理策略中的显著临床价值；耐赋康®对特殊人群的疗效也得到验证，巩固了其IgA肾病一线治疗的基石地位。
据介绍，此次ASN大会公布的研究结合了多项中国真实世界研究(RWS)证据，系统印证了耐赋康®通过靶向肠道黏膜免疫、从源头干预疾病进程的独特价值，为IgA肾病全病程规范化治疗提供了关键循证支持。超七成中国IgA肾病患者诊断时已存在进展风险，存在治疗启动滞后的问题。目前，中国约有500万的IgA肾病患者，每年新增确诊患者超过12万人，存在巨大未被满足的临床需求。因此，通过尽早长期对因治疗延缓疾病进展、保护患者肾功能，对IgA肾病的治疗具有至关重要的意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.